nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextropropoxyphene—CYP2C8—Tazarotene—psoriasis	0.0948	0.124	CbGbCtD
Dextropropoxyphene—CYP2D6—Hydroxyurea—psoriasis	0.0426	0.0557	CbGbCtD
Dextropropoxyphene—CYP2C8—Cholecalciferol—psoriasis	0.0405	0.0529	CbGbCtD
Dextropropoxyphene—CYP3A7—Hydrocortisone—psoriasis	0.039	0.051	CbGbCtD
Dextropropoxyphene—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.039	0.051	CbGbCtD
Dextropropoxyphene—CYP3A7—Cyclosporine—psoriasis	0.0369	0.0482	CbGbCtD
Dextropropoxyphene—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0369	0.0482	CbGbCtD
Dextropropoxyphene—CYP2C8—Mycophenolate mofetil—psoriasis	0.0351	0.0459	CbGbCtD
Dextropropoxyphene—CYP3A4—Calcitriol—psoriasis	0.0318	0.0416	CbGbCtD
Dextropropoxyphene—CYP2C9—Cholecalciferol—psoriasis	0.0282	0.0369	CbGbCtD
Dextropropoxyphene—CYP2C8—Hydrocortisone—psoriasis	0.0281	0.0368	CbGbCtD
Dextropropoxyphene—CYP2C8—Cyclosporine—psoriasis	0.0266	0.0348	CbGbCtD
Dextropropoxyphene—CYP2D6—Cholecalciferol—psoriasis	0.0258	0.0337	CbGbCtD
Dextropropoxyphene—CYP3A4—Methoxsalen—psoriasis	0.0248	0.0324	CbGbCtD
Dextropropoxyphene—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0243	0.0317	CbGbCtD
Dextropropoxyphene—CYP3A7—Dexamethasone—psoriasis	0.0243	0.0317	CbGbCtD
Dextropropoxyphene—CYP2C9—Cyclosporine—psoriasis	0.0185	0.0242	CbGbCtD
Dextropropoxyphene—CYP2C8—Dexamethasone—psoriasis	0.0175	0.0229	CbGbCtD
Dextropropoxyphene—CYP2D6—Cyclosporine—psoriasis	0.017	0.0222	CbGbCtD
Dextropropoxyphene—CYP3A4—Cholecalciferol—psoriasis	0.0164	0.0215	CbGbCtD
Dextropropoxyphene—CYP3A4—Triamcinolone—psoriasis	0.0142	0.0186	CbGbCtD
Dextropropoxyphene—CYP3A4—Mycophenolate mofetil—psoriasis	0.0142	0.0186	CbGbCtD
Dextropropoxyphene—CYP2C9—Dexamethasone—psoriasis	0.0122	0.016	CbGbCtD
Dextropropoxyphene—CYP3A4—Betamethasone—psoriasis	0.0122	0.016	CbGbCtD
Dextropropoxyphene—CYP3A4—Prednisolone—psoriasis	0.012	0.0157	CbGbCtD
Dextropropoxyphene—CYP3A4—Hydrocortisone—psoriasis	0.0114	0.0149	CbGbCtD
Dextropropoxyphene—CYP3A4—Prednisone—psoriasis	0.0114	0.0149	CbGbCtD
Dextropropoxyphene—CYP2D6—Dexamethasone—psoriasis	0.0112	0.0146	CbGbCtD
Dextropropoxyphene—CYP3A4—Cyclosporine—psoriasis	0.0108	0.0141	CbGbCtD
Dextropropoxyphene—CYP3A4—Dexamethasone—psoriasis	0.0071	0.00928	CbGbCtD
Dextropropoxyphene—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00153	0.0586	CbGpPWpGaD
Dextropropoxyphene—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.00151	0.058	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00126	0.0481	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00124	0.0477	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00117	0.0449	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000948	0.0363	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000778	0.0298	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000772	0.0296	CbGpPWpGaD
Dextropropoxyphene—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000629	0.0241	CbGpPWpGaD
Dextropropoxyphene—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000621	0.0238	CbGpPWpGaD
Dextropropoxyphene—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00051	0.0195	CbGpPWpGaD
Dextropropoxyphene—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000509	0.0195	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000394	0.0151	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000389	0.0149	CbGpPWpGaD
Dextropropoxyphene—OPRD1—G alpha (i) signalling events—HCAR2—psoriasis	0.000366	0.014	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000323	0.0124	CbGpPWpGaD
Dextropropoxyphene—OPRK1—G alpha (i) signalling events—HCAR2—psoriasis	0.000321	0.0123	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00032	0.0123	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000319	0.0122	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000319	0.0122	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000316	0.0121	CbGpPWpGaD
Dextropropoxyphene—Agitation—Mycophenolate mofetil—psoriasis	0.000303	0.00145	CcSEcCtD
Dextropropoxyphene—Malnutrition—Hydrocortisone—psoriasis	0.000301	0.00144	CcSEcCtD
Dextropropoxyphene—Dyspepsia—Mycophenolic acid—psoriasis	0.0003	0.00144	CcSEcCtD
Dextropropoxyphene—Bradycardia—Dexamethasone—psoriasis	0.0003	0.00144	CcSEcCtD
Dextropropoxyphene—Bradycardia—Betamethasone—psoriasis	0.0003	0.00144	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Hydroxyurea—psoriasis	0.0003	0.00144	CcSEcCtD
Dextropropoxyphene—Syncope—Mycophenolate mofetil—psoriasis	0.000296	0.00141	CcSEcCtD
Dextropropoxyphene—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000295	0.00141	CcSEcCtD
Dextropropoxyphene—Hallucination—Dexamethasone—psoriasis	0.000294	0.0014	CcSEcCtD
Dextropropoxyphene—Hallucination—Betamethasone—psoriasis	0.000294	0.0014	CcSEcCtD
Dextropropoxyphene—Convulsion—Cyclosporine—psoriasis	0.000293	0.0014	CcSEcCtD
Dextropropoxyphene—Asthenia—Hydroxyurea—psoriasis	0.000292	0.0014	CcSEcCtD
Dextropropoxyphene—Ataxia—Methotrexate—psoriasis	0.000292	0.0014	CcSEcCtD
Dextropropoxyphene—Constipation—Mycophenolic acid—psoriasis	0.000292	0.0014	CcSEcCtD
Dextropropoxyphene—OPRD1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000291	0.0111	CbGpPWpGaD
Dextropropoxyphene—Arrhythmia—Triamcinolone—psoriasis	0.000291	0.00139	CcSEcCtD
Dextropropoxyphene—Vision blurred—Prednisolone—psoriasis	0.00029	0.00139	CcSEcCtD
Dextropropoxyphene—Loss of consciousness—Mycophenolate mofetil—psoriasis	0.00029	0.00139	CcSEcCtD
Dextropropoxyphene—Liver function test abnormal—Methotrexate—psoriasis	0.000287	0.00137	CcSEcCtD
Dextropropoxyphene—Convulsion—Mycophenolate mofetil—psoriasis	0.000286	0.00137	CcSEcCtD
Dextropropoxyphene—Discomfort—Cyclosporine—psoriasis	0.000285	0.00136	CcSEcCtD
Dextropropoxyphene—Visual impairment—Dexamethasone—psoriasis	0.000284	0.00136	CcSEcCtD
Dextropropoxyphene—Visual impairment—Betamethasone—psoriasis	0.000284	0.00136	CcSEcCtD
Dextropropoxyphene—Acute coronary syndrome—Prednisone—psoriasis	0.000282	0.00135	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Mycophenolic acid—psoriasis	0.000281	0.00134	CcSEcCtD
Dextropropoxyphene—Myocardial infarction—Prednisone—psoriasis	0.000281	0.00134	CcSEcCtD
Dextropropoxyphene—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000279	0.00133	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Hydroxyurea—psoriasis	0.000279	0.00133	CcSEcCtD
Dextropropoxyphene—Confusional state—Cyclosporine—psoriasis	0.000278	0.00133	CcSEcCtD
Dextropropoxyphene—Discomfort—Mycophenolate mofetil—psoriasis	0.000278	0.00133	CcSEcCtD
Dextropropoxyphene—Syncope—Prednisolone—psoriasis	0.000276	0.00132	CcSEcCtD
Dextropropoxyphene—Eye disorder—Dexamethasone—psoriasis	0.000276	0.00132	CcSEcCtD
Dextropropoxyphene—Eye disorder—Betamethasone—psoriasis	0.000276	0.00132	CcSEcCtD
Dextropropoxyphene—Confusional state—Mycophenolate mofetil—psoriasis	0.000272	0.0013	CcSEcCtD
Dextropropoxyphene—OPRM1—G alpha (i) signalling events—HCAR2—psoriasis	0.000271	0.0104	CbGpPWpGaD
Dextropropoxyphene—Nervous system disorder—Cyclosporine—psoriasis	0.000271	0.00129	CcSEcCtD
Dextropropoxyphene—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000271	0.0104	CbGpPWpGaD
Dextropropoxyphene—Loss of consciousness—Prednisolone—psoriasis	0.000271	0.00129	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Mycophenolic acid—psoriasis	0.00027	0.00129	CcSEcCtD
Dextropropoxyphene—Syncope—Hydrocortisone—psoriasis	0.00027	0.00129	CcSEcCtD
Dextropropoxyphene—Dizziness—Hydroxyurea—psoriasis	0.000269	0.00129	CcSEcCtD
Dextropropoxyphene—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000267	0.0102	CbGpPWpGaD
Dextropropoxyphene—Convulsion—Prednisolone—psoriasis	0.000267	0.00128	CcSEcCtD
Dextropropoxyphene—Shock—Mycophenolate mofetil—psoriasis	0.000265	0.00127	CcSEcCtD
Dextropropoxyphene—Loss of consciousness—Hydrocortisone—psoriasis	0.000264	0.00126	CcSEcCtD
Dextropropoxyphene—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000264	0.00126	CcSEcCtD
Dextropropoxyphene—Arrhythmia—Betamethasone—psoriasis	0.000264	0.00126	CcSEcCtD
Dextropropoxyphene—Arrhythmia—Dexamethasone—psoriasis	0.000264	0.00126	CcSEcCtD
Dextropropoxyphene—Tachycardia—Mycophenolate mofetil—psoriasis	0.000263	0.00126	CcSEcCtD
Dextropropoxyphene—OPRM1—TCR Signaling Pathway—REL—psoriasis	0.000262	0.01	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000262	0.01	CbGpPWpGaD
Dextropropoxyphene—Bradycardia—Prednisone—psoriasis	0.000262	0.00125	CcSEcCtD
Dextropropoxyphene—Convulsion—Hydrocortisone—psoriasis	0.000261	0.00125	CcSEcCtD
Dextropropoxyphene—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00026	0.00995	CbGpPWpGaD
Dextropropoxyphene—Vomiting—Hydroxyurea—psoriasis	0.000259	0.00124	CcSEcCtD
Dextropropoxyphene—Discomfort—Prednisolone—psoriasis	0.000259	0.00124	CcSEcCtD
Dextropropoxyphene—Rash—Hydroxyurea—psoriasis	0.000257	0.00123	CcSEcCtD
Dextropropoxyphene—Dermatitis—Hydroxyurea—psoriasis	0.000257	0.00123	CcSEcCtD
Dextropropoxyphene—Hallucination—Prednisone—psoriasis	0.000256	0.00122	CcSEcCtD
Dextropropoxyphene—Headache—Hydroxyurea—psoriasis	0.000255	0.00122	CcSEcCtD
Dextropropoxyphene—OPRK1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000255	0.00977	CbGpPWpGaD
Dextropropoxyphene—Syncope—Triamcinolone—psoriasis	0.000254	0.00121	CcSEcCtD
Dextropropoxyphene—Discomfort—Hydrocortisone—psoriasis	0.000253	0.00121	CcSEcCtD
Dextropropoxyphene—Hypotension—Mycophenolate mofetil—psoriasis	0.000252	0.0012	CcSEcCtD
Dextropropoxyphene—Insomnia—Cyclosporine—psoriasis	0.00025	0.00119	CcSEcCtD
Dextropropoxyphene—Loss of consciousness—Triamcinolone—psoriasis	0.000249	0.00119	CcSEcCtD
Dextropropoxyphene—Shock—Prednisolone—psoriasis	0.000247	0.00118	CcSEcCtD
Dextropropoxyphene—Dyspnoea—Cyclosporine—psoriasis	0.000246	0.00118	CcSEcCtD
Dextropropoxyphene—Somnolence—Cyclosporine—psoriasis	0.000245	0.00117	CcSEcCtD
Dextropropoxyphene—Convulsion—Triamcinolone—psoriasis	0.000245	0.00117	CcSEcCtD
Dextropropoxyphene—Tachycardia—Prednisolone—psoriasis	0.000245	0.00117	CcSEcCtD
Dextropropoxyphene—Asthenia—Mycophenolic acid—psoriasis	0.000245	0.00117	CcSEcCtD
Dextropropoxyphene—Insomnia—Mycophenolate mofetil—psoriasis	0.000244	0.00116	CcSEcCtD
Dextropropoxyphene—Dyspepsia—Cyclosporine—psoriasis	0.000243	0.00116	CcSEcCtD
Dextropropoxyphene—Nausea—Hydroxyurea—psoriasis	0.000242	0.00116	CcSEcCtD
Dextropropoxyphene—Shock—Hydrocortisone—psoriasis	0.000241	0.00115	CcSEcCtD
Dextropropoxyphene—Nervous system disorder—Hydrocortisone—psoriasis	0.000241	0.00115	CcSEcCtD
Dextropropoxyphene—Eye disorder—Prednisone—psoriasis	0.00024	0.00115	CcSEcCtD
Dextropropoxyphene—Dyspnoea—Mycophenolate mofetil—psoriasis	0.00024	0.00115	CcSEcCtD
Dextropropoxyphene—Tachycardia—Hydrocortisone—psoriasis	0.00024	0.00114	CcSEcCtD
Dextropropoxyphene—Somnolence—Mycophenolate mofetil—psoriasis	0.000239	0.00114	CcSEcCtD
Dextropropoxyphene—Drowsiness—Methotrexate—psoriasis	0.000239	0.00114	CcSEcCtD
Dextropropoxyphene—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000238	0.00114	CcSEcCtD
Dextropropoxyphene—Discomfort—Triamcinolone—psoriasis	0.000238	0.00114	CcSEcCtD
Dextropropoxyphene—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000237	0.00113	CcSEcCtD
Dextropropoxyphene—Constipation—Cyclosporine—psoriasis	0.000236	0.00113	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Mycophenolic acid—psoriasis	0.000234	0.00112	CcSEcCtD
Dextropropoxyphene—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000233	0.00111	CcSEcCtD
Dextropropoxyphene—Immune system disorder—Prednisone—psoriasis	0.000232	0.00111	CcSEcCtD
Dextropropoxyphene—Syncope—Betamethasone—psoriasis	0.00023	0.0011	CcSEcCtD
Dextropropoxyphene—Syncope—Dexamethasone—psoriasis	0.00023	0.0011	CcSEcCtD
Dextropropoxyphene—Constipation—Mycophenolate mofetil—psoriasis	0.00023	0.0011	CcSEcCtD
Dextropropoxyphene—Arrhythmia—Prednisone—psoriasis	0.00023	0.0011	CcSEcCtD
Dextropropoxyphene—Hypotension—Hydrocortisone—psoriasis	0.000229	0.0011	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Cyclosporine—psoriasis	0.000228	0.00109	CcSEcCtD
Dextropropoxyphene—Shock—Triamcinolone—psoriasis	0.000227	0.00109	CcSEcCtD
Dextropropoxyphene—Insomnia—Prednisolone—psoriasis	0.000227	0.00109	CcSEcCtD
Dextropropoxyphene—Hepatobiliary disease—Methotrexate—psoriasis	0.000226	0.00108	CcSEcCtD
Dextropropoxyphene—Gastrointestinal pain—Cyclosporine—psoriasis	0.000226	0.00108	CcSEcCtD
Dextropropoxyphene—Loss of consciousness—Betamethasone—psoriasis	0.000226	0.00108	CcSEcCtD
Dextropropoxyphene—Loss of consciousness—Dexamethasone—psoriasis	0.000226	0.00108	CcSEcCtD
Dextropropoxyphene—Dizziness—Mycophenolic acid—psoriasis	0.000226	0.00108	CcSEcCtD
Dextropropoxyphene—Tachycardia—Triamcinolone—psoriasis	0.000226	0.00108	CcSEcCtD
Dextropropoxyphene—OPRD1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000225	0.00863	CbGpPWpGaD
Dextropropoxyphene—OPRM1—IL4-mediated signaling events—SOCS1—psoriasis	0.000225	0.00863	CbGpPWpGaD
Dextropropoxyphene—Malnutrition—Prednisone—psoriasis	0.000224	0.00107	CcSEcCtD
Dextropropoxyphene—Convulsion—Dexamethasone—psoriasis	0.000223	0.00106	CcSEcCtD
Dextropropoxyphene—Convulsion—Betamethasone—psoriasis	0.000223	0.00106	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000222	0.00106	CcSEcCtD
Dextropropoxyphene—Insomnia—Hydrocortisone—psoriasis	0.000222	0.00106	CcSEcCtD
Dextropropoxyphene—OPRD1—GPCR ligand binding—HCAR2—psoriasis	0.000222	0.00849	CbGpPWpGaD
Dextropropoxyphene—OPRM1—TCR Signaling Pathway—IL17A—psoriasis	0.000221	0.00845	CbGpPWpGaD
Dextropropoxyphene—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.00022	0.00105	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Cyclosporine—psoriasis	0.000218	0.00104	CcSEcCtD
Dextropropoxyphene—Vomiting—Mycophenolic acid—psoriasis	0.000217	0.00104	CcSEcCtD
Dextropropoxyphene—Discomfort—Betamethasone—psoriasis	0.000216	0.00103	CcSEcCtD
Dextropropoxyphene—Discomfort—Dexamethasone—psoriasis	0.000216	0.00103	CcSEcCtD
Dextropropoxyphene—Dyspepsia—Hydrocortisone—psoriasis	0.000216	0.00103	CcSEcCtD
Dextropropoxyphene—OPRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000216	0.00826	CbGpPWpGaD
Dextropropoxyphene—Rash—Mycophenolic acid—psoriasis	0.000215	0.00103	CcSEcCtD
Dextropropoxyphene—Dermatitis—Mycophenolic acid—psoriasis	0.000215	0.00103	CcSEcCtD
Dextropropoxyphene—Headache—Mycophenolic acid—psoriasis	0.000214	0.00102	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000213	0.00102	CcSEcCtD
Dextropropoxyphene—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000212	0.00101	CcSEcCtD
Dextropropoxyphene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000211	0.00809	CbGpPWpGaD
Dextropropoxyphene—Vision blurred—Prednisone—psoriasis	0.000211	0.00101	CcSEcCtD
Dextropropoxyphene—Insomnia—Triamcinolone—psoriasis	0.000209	0.000999	CcSEcCtD
Dextropropoxyphene—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000209	0.00799	CbGpPWpGaD
Dextropropoxyphene—Feeling abnormal—Prednisolone—psoriasis	0.000207	0.00099	CcSEcCtD
Dextropropoxyphene—Visual impairment—Methotrexate—psoriasis	0.000207	0.00099	CcSEcCtD
Dextropropoxyphene—Shock—Dexamethasone—psoriasis	0.000206	0.000986	CcSEcCtD
Dextropropoxyphene—Shock—Betamethasone—psoriasis	0.000206	0.000986	CcSEcCtD
Dextropropoxyphene—Dyspnoea—Triamcinolone—psoriasis	0.000206	0.000985	CcSEcCtD
Dextropropoxyphene—Nervous system disorder—Dexamethasone—psoriasis	0.000206	0.000983	CcSEcCtD
Dextropropoxyphene—Nervous system disorder—Betamethasone—psoriasis	0.000206	0.000983	CcSEcCtD
Dextropropoxyphene—Agitation—Prednisone—psoriasis	0.000206	0.000983	CcSEcCtD
Dextropropoxyphene—Tachycardia—Betamethasone—psoriasis	0.000205	0.000978	CcSEcCtD
Dextropropoxyphene—Tachycardia—Dexamethasone—psoriasis	0.000205	0.000978	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Cyclosporine—psoriasis	0.000203	0.000973	CcSEcCtD
Dextropropoxyphene—Dyspepsia—Triamcinolone—psoriasis	0.000203	0.000972	CcSEcCtD
Dextropropoxyphene—Nausea—Mycophenolic acid—psoriasis	0.000203	0.000969	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Hydrocortisone—psoriasis	0.000202	0.000967	CcSEcCtD
Dextropropoxyphene—OPRM1—IL4-mediated signaling events—IL10—psoriasis	0.000202	0.00774	CbGpPWpGaD
Dextropropoxyphene—Eye disorder—Methotrexate—psoriasis	0.000201	0.00096	CcSEcCtD
Dextropropoxyphene—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000201	0.000959	CcSEcCtD
Dextropropoxyphene—Syncope—Prednisone—psoriasis	0.000201	0.000959	CcSEcCtD
Dextropropoxyphene—Cardiac disorder—Methotrexate—psoriasis	0.000199	0.000953	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000198	0.000949	CcSEcCtD
Dextropropoxyphene—Asthenia—Cyclosporine—psoriasis	0.000198	0.000947	CcSEcCtD
Dextropropoxyphene—OPRK1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000198	0.00757	CbGpPWpGaD
Dextropropoxyphene—Loss of consciousness—Prednisone—psoriasis	0.000197	0.00094	CcSEcCtD
Dextropropoxyphene—OPRM1—IL4-mediated signaling events—IL4—psoriasis	0.000197	0.00753	CbGpPWpGaD
Dextropropoxyphene—Hypotension—Dexamethasone—psoriasis	0.000196	0.000937	CcSEcCtD
Dextropropoxyphene—Hypotension—Betamethasone—psoriasis	0.000196	0.000937	CcSEcCtD
Dextropropoxyphene—OPRK1—GPCR ligand binding—HCAR2—psoriasis	0.000194	0.00744	CbGpPWpGaD
Dextropropoxyphene—Immune system disorder—Methotrexate—psoriasis	0.000194	0.000927	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Hydrocortisone—psoriasis	0.000194	0.000927	CcSEcCtD
Dextropropoxyphene—Convulsion—Prednisone—psoriasis	0.000194	0.000927	CcSEcCtD
Dextropropoxyphene—Mediastinal disorder—Methotrexate—psoriasis	0.000194	0.000925	CcSEcCtD
Dextropropoxyphene—Asthenia—Mycophenolate mofetil—psoriasis	0.000193	0.000924	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Triamcinolone—psoriasis	0.00019	0.00091	CcSEcCtD
Dextropropoxyphene—OPRD1—G alpha (i) signalling events—CCL20—psoriasis	0.00019	0.00728	CbGpPWpGaD
Dextropropoxyphene—Insomnia—Dexamethasone—psoriasis	0.00019	0.000907	CcSEcCtD
Dextropropoxyphene—Insomnia—Betamethasone—psoriasis	0.00019	0.000907	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Cyclosporine—psoriasis	0.000189	0.000903	CcSEcCtD
Dextropropoxyphene—Discomfort—Prednisone—psoriasis	0.000188	0.0009	CcSEcCtD
Dextropropoxyphene—Malnutrition—Methotrexate—psoriasis	0.000187	0.000894	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Prednisolone—psoriasis	0.000185	0.000885	CcSEcCtD
Dextropropoxyphene—Dyspepsia—Betamethasone—psoriasis	0.000185	0.000882	CcSEcCtD
Dextropropoxyphene—Dyspepsia—Dexamethasone—psoriasis	0.000185	0.000882	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000184	0.000881	CcSEcCtD
Dextropropoxyphene—Dizziness—Cyclosporine—psoriasis	0.000183	0.000873	CcSEcCtD
Dextropropoxyphene—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000181	0.000865	CcSEcCtD
Dextropropoxyphene—Gastrointestinal disorder—Betamethasone—psoriasis	0.000181	0.000865	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Hydrocortisone—psoriasis	0.000181	0.000864	CcSEcCtD
Dextropropoxyphene—Shock—Prednisone—psoriasis	0.00018	0.000859	CcSEcCtD
Dextropropoxyphene—Nervous system disorder—Prednisone—psoriasis	0.000179	0.000856	CcSEcCtD
Dextropropoxyphene—Tachycardia—Prednisone—psoriasis	0.000178	0.000852	CcSEcCtD
Dextropropoxyphene—Dizziness—Mycophenolate mofetil—psoriasis	0.000178	0.000852	CcSEcCtD
Dextropropoxyphene—Vision blurred—Methotrexate—psoriasis	0.000176	0.000842	CcSEcCtD
Dextropropoxyphene—Asthenia—Hydrocortisone—psoriasis	0.000176	0.000842	CcSEcCtD
Dextropropoxyphene—Vomiting—Cyclosporine—psoriasis	0.000176	0.000839	CcSEcCtD
Dextropropoxyphene—Rash—Cyclosporine—psoriasis	0.000174	0.000832	CcSEcCtD
Dextropropoxyphene—Dermatitis—Cyclosporine—psoriasis	0.000174	0.000832	CcSEcCtD
Dextropropoxyphene—Headache—Cyclosporine—psoriasis	0.000173	0.000827	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Betamethasone—psoriasis	0.000173	0.000826	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Dexamethasone—psoriasis	0.000173	0.000826	CcSEcCtD
Dextropropoxyphene—Gastrointestinal pain—Betamethasone—psoriasis	0.000171	0.00082	CcSEcCtD
Dextropropoxyphene—Gastrointestinal pain—Dexamethasone—psoriasis	0.000171	0.00082	CcSEcCtD
Dextropropoxyphene—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000171	0.00656	CbGpPWpGaD
Dextropropoxyphene—Vomiting—Mycophenolate mofetil—psoriasis	0.000171	0.000819	CcSEcCtD
Dextropropoxyphene—Hypersensitivity—Triamcinolone—psoriasis	0.00017	0.000814	CcSEcCtD
Dextropropoxyphene—Rash—Mycophenolate mofetil—psoriasis	0.00017	0.000812	CcSEcCtD
Dextropropoxyphene—Dermatitis—Mycophenolate mofetil—psoriasis	0.00017	0.000811	CcSEcCtD
Dextropropoxyphene—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.00017	0.00649	CbGpPWpGaD
Dextropropoxyphene—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000169	0.00647	CbGpPWpGaD
Dextropropoxyphene—Headache—Mycophenolate mofetil—psoriasis	0.000169	0.000807	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Hydrocortisone—psoriasis	0.000168	0.000803	CcSEcCtD
Dextropropoxyphene—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000167	0.0064	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000167	0.0064	CbGpPWpGaD
Dextropropoxyphene—OPRK1—G alpha (i) signalling events—CCL20—psoriasis	0.000167	0.00638	CbGpPWpGaD
Dextropropoxyphene—Dizziness—Prednisolone—psoriasis	0.000166	0.000794	CcSEcCtD
Dextropropoxyphene—Asthenia—Triamcinolone—psoriasis	0.000166	0.000793	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Betamethasone—psoriasis	0.000166	0.000792	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Dexamethasone—psoriasis	0.000166	0.000792	CcSEcCtD
Dextropropoxyphene—Insomnia—Prednisone—psoriasis	0.000165	0.000789	CcSEcCtD
Dextropropoxyphene—OPRM1—GPCR ligand binding—HCAR2—psoriasis	0.000164	0.00629	CbGpPWpGaD
Dextropropoxyphene—Nausea—Cyclosporine—psoriasis	0.000164	0.000784	CcSEcCtD
Dextropropoxyphene—Dizziness—Hydrocortisone—psoriasis	0.000162	0.000776	CcSEcCtD
Dextropropoxyphene—Convulsion—Methotrexate—psoriasis	0.000162	0.000774	CcSEcCtD
Dextropropoxyphene—Dyspepsia—Prednisone—psoriasis	0.000161	0.000768	CcSEcCtD
Dextropropoxyphene—Nausea—Mycophenolate mofetil—psoriasis	0.00016	0.000765	CcSEcCtD
Dextropropoxyphene—Rash—Prednisolone—psoriasis	0.000158	0.000757	CcSEcCtD
Dextropropoxyphene—Dermatitis—Prednisolone—psoriasis	0.000158	0.000757	CcSEcCtD
Dextropropoxyphene—Headache—Prednisolone—psoriasis	0.000157	0.000753	CcSEcCtD
Dextropropoxyphene—Discomfort—Methotrexate—psoriasis	0.000157	0.000752	CcSEcCtD
Dextropropoxyphene—Constipation—Prednisone—psoriasis	0.000156	0.000746	CcSEcCtD
Dextropropoxyphene—Vomiting—Hydrocortisone—psoriasis	0.000156	0.000746	CcSEcCtD
Dextropropoxyphene—Rash—Hydrocortisone—psoriasis	0.000155	0.00074	CcSEcCtD
Dextropropoxyphene—Dermatitis—Hydrocortisone—psoriasis	0.000155	0.000739	CcSEcCtD
Dextropropoxyphene—Confusional state—Methotrexate—psoriasis	0.000154	0.000736	CcSEcCtD
Dextropropoxyphene—Headache—Hydrocortisone—psoriasis	0.000154	0.000735	CcSEcCtD
Dextropropoxyphene—Dizziness—Triamcinolone—psoriasis	0.000153	0.00073	CcSEcCtD
Dextropropoxyphene—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000151	0.00579	CbGpPWpGaD
Dextropropoxyphene—Feeling abnormal—Prednisone—psoriasis	0.00015	0.000719	CcSEcCtD
Dextropropoxyphene—Asthenia—Dexamethasone—psoriasis	0.00015	0.000719	CcSEcCtD
Dextropropoxyphene—Asthenia—Betamethasone—psoriasis	0.00015	0.000719	CcSEcCtD
Dextropropoxyphene—Nervous system disorder—Methotrexate—psoriasis	0.00015	0.000715	CcSEcCtD
Dextropropoxyphene—Gastrointestinal pain—Prednisone—psoriasis	0.000149	0.000714	CcSEcCtD
Dextropropoxyphene—Nausea—Prednisolone—psoriasis	0.000149	0.000713	CcSEcCtD
Dextropropoxyphene—OPRM1—TCR Signaling Pathway—CD8A—psoriasis	0.000148	0.00568	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000147	0.00564	CbGpPWpGaD
Dextropropoxyphene—Vomiting—Triamcinolone—psoriasis	0.000147	0.000702	CcSEcCtD
Dextropropoxyphene—Nausea—Hydrocortisone—psoriasis	0.000146	0.000697	CcSEcCtD
Dextropropoxyphene—Rash—Triamcinolone—psoriasis	0.000146	0.000696	CcSEcCtD
Dextropropoxyphene—Dermatitis—Triamcinolone—psoriasis	0.000146	0.000696	CcSEcCtD
Dextropropoxyphene—Headache—Triamcinolone—psoriasis	0.000145	0.000692	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Prednisone—psoriasis	0.000144	0.00069	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Dexamethasone—psoriasis	0.000143	0.000686	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Betamethasone—psoriasis	0.000143	0.000686	CcSEcCtD
Dextropropoxyphene—Hypotension—Methotrexate—psoriasis	0.000143	0.000682	CcSEcCtD
Dextropropoxyphene—OPRM1—G alpha (i) signalling events—CCL20—psoriasis	0.000141	0.0054	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000139	0.00533	CbGpPWpGaD
Dextropropoxyphene—Dizziness—Betamethasone—psoriasis	0.000139	0.000663	CcSEcCtD
Dextropropoxyphene—Dizziness—Dexamethasone—psoriasis	0.000139	0.000663	CcSEcCtD
Dextropropoxyphene—Insomnia—Methotrexate—psoriasis	0.000138	0.00066	CcSEcCtD
Dextropropoxyphene—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000138	0.00528	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000137	0.00526	CbGpPWpGaD
Dextropropoxyphene—Nausea—Triamcinolone—psoriasis	0.000137	0.000656	CcSEcCtD
Dextropropoxyphene—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000136	0.00521	CbGpPWpGaD
Dextropropoxyphene—Dyspnoea—Methotrexate—psoriasis	0.000136	0.00065	CcSEcCtD
Dextropropoxyphene—Somnolence—Methotrexate—psoriasis	0.000136	0.000649	CcSEcCtD
Dextropropoxyphene—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000135	0.00517	CbGpPWpGaD
Dextropropoxyphene—Hypersensitivity—Prednisone—psoriasis	0.000135	0.000643	CcSEcCtD
Dextropropoxyphene—Dyspepsia—Methotrexate—psoriasis	0.000134	0.000642	CcSEcCtD
Dextropropoxyphene—Vomiting—Dexamethasone—psoriasis	0.000133	0.000637	CcSEcCtD
Dextropropoxyphene—Vomiting—Betamethasone—psoriasis	0.000133	0.000637	CcSEcCtD
Dextropropoxyphene—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000133	0.00508	CbGpPWpGaD
Dextropropoxyphene—Rash—Betamethasone—psoriasis	0.000132	0.000632	CcSEcCtD
Dextropropoxyphene—Rash—Dexamethasone—psoriasis	0.000132	0.000632	CcSEcCtD
Dextropropoxyphene—Dermatitis—Dexamethasone—psoriasis	0.000132	0.000631	CcSEcCtD
Dextropropoxyphene—Dermatitis—Betamethasone—psoriasis	0.000132	0.000631	CcSEcCtD
Dextropropoxyphene—Gastrointestinal disorder—Methotrexate—psoriasis	0.000132	0.00063	CcSEcCtD
Dextropropoxyphene—Headache—Dexamethasone—psoriasis	0.000131	0.000628	CcSEcCtD
Dextropropoxyphene—Headache—Betamethasone—psoriasis	0.000131	0.000628	CcSEcCtD
Dextropropoxyphene—Asthenia—Prednisone—psoriasis	0.000131	0.000626	CcSEcCtD
Dextropropoxyphene—Feeling abnormal—Methotrexate—psoriasis	0.000126	0.000601	CcSEcCtD
Dextropropoxyphene—OPRD1—GPCR downstream signaling—HCAR2—psoriasis	0.000125	0.0048	CbGpPWpGaD
Dextropropoxyphene—Diarrhoea—Prednisone—psoriasis	0.000125	0.000597	CcSEcCtD
Dextropropoxyphene—Gastrointestinal pain—Methotrexate—psoriasis	0.000125	0.000597	CcSEcCtD
Dextropropoxyphene—Nausea—Dexamethasone—psoriasis	0.000125	0.000595	CcSEcCtD
Dextropropoxyphene—Nausea—Betamethasone—psoriasis	0.000125	0.000595	CcSEcCtD
Dextropropoxyphene—Dizziness—Prednisone—psoriasis	0.000121	0.000577	CcSEcCtD
Dextropropoxyphene—Abdominal pain—Methotrexate—psoriasis	0.000121	0.000577	CcSEcCtD
Dextropropoxyphene—Vomiting—Prednisone—psoriasis	0.000116	0.000555	CcSEcCtD
Dextropropoxyphene—Rash—Prednisone—psoriasis	0.000115	0.00055	CcSEcCtD
Dextropropoxyphene—OPRD1—GPCR ligand binding—CCL20—psoriasis	0.000115	0.00441	CbGpPWpGaD
Dextropropoxyphene—Dermatitis—Prednisone—psoriasis	0.000115	0.00055	CcSEcCtD
Dextropropoxyphene—OPRM1—TCR Signaling Pathway—NFKBIA—psoriasis	0.000115	0.0044	CbGpPWpGaD
Dextropropoxyphene—Headache—Prednisone—psoriasis	0.000114	0.000547	CcSEcCtD
Dextropropoxyphene—OPRD1—Signaling by GPCR—HCAR2—psoriasis	0.000114	0.00436	CbGpPWpGaD
Dextropropoxyphene—Hypersensitivity—Methotrexate—psoriasis	0.000112	0.000537	CcSEcCtD
Dextropropoxyphene—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000112	0.00429	CbGpPWpGaD
Dextropropoxyphene—OPRK1—GPCR downstream signaling—HCAR2—psoriasis	0.00011	0.00421	CbGpPWpGaD
Dextropropoxyphene—Asthenia—Methotrexate—psoriasis	0.000109	0.000523	CcSEcCtD
Dextropropoxyphene—Nausea—Prednisone—psoriasis	0.000108	0.000518	CcSEcCtD
Dextropropoxyphene—Diarrhoea—Methotrexate—psoriasis	0.000104	0.000499	CcSEcCtD
Dextropropoxyphene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000103	0.00393	CbGpPWpGaD
Dextropropoxyphene—OPRK1—GPCR ligand binding—CCL20—psoriasis	0.000101	0.00387	CbGpPWpGaD
Dextropropoxyphene—Dizziness—Methotrexate—psoriasis	0.000101	0.000482	CcSEcCtD
Dextropropoxyphene—OPRK1—Signaling by GPCR—HCAR2—psoriasis	9.97e-05	0.00382	CbGpPWpGaD
Dextropropoxyphene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.71e-05	0.00372	CbGpPWpGaD
Dextropropoxyphene—Vomiting—Methotrexate—psoriasis	9.7e-05	0.000464	CcSEcCtD
Dextropropoxyphene—Rash—Methotrexate—psoriasis	9.62e-05	0.00046	CcSEcCtD
Dextropropoxyphene—Dermatitis—Methotrexate—psoriasis	9.61e-05	0.00046	CcSEcCtD
Dextropropoxyphene—Headache—Methotrexate—psoriasis	9.56e-05	0.000457	CcSEcCtD
Dextropropoxyphene—OPRM1—GPCR downstream signaling—HCAR2—psoriasis	9.28e-05	0.00355	CbGpPWpGaD
Dextropropoxyphene—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.1e-05	0.00349	CbGpPWpGaD
Dextropropoxyphene—Nausea—Methotrexate—psoriasis	9.06e-05	0.000433	CcSEcCtD
Dextropropoxyphene—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.98e-05	0.00344	CbGpPWpGaD
Dextropropoxyphene—OPRM1—GPCR ligand binding—CCL20—psoriasis	8.53e-05	0.00327	CbGpPWpGaD
Dextropropoxyphene—OPRM1—TCR Signaling Pathway—CD4—psoriasis	8.52e-05	0.00326	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling by GPCR—HCAR2—psoriasis	8.43e-05	0.00323	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	8.03e-05	0.00307	CbGpPWpGaD
Dextropropoxyphene—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.85e-05	0.00301	CbGpPWpGaD
Dextropropoxyphene—OPRM1—TCR Signaling Pathway—JUN—psoriasis	7.62e-05	0.00292	CbGpPWpGaD
Dextropropoxyphene—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	7.34e-05	0.00281	CbGpPWpGaD
Dextropropoxyphene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.77e-05	0.00259	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—HCAR2—psoriasis	6.72e-05	0.00257	CbGpPWpGaD
Dextropropoxyphene—OPRD1—GPCR downstream signaling—CCL20—psoriasis	6.5e-05	0.00249	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Peptide ligand-binding receptors—CXCL8—psoriasis	6.09e-05	0.00233	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling by GPCR—CCL20—psoriasis	5.91e-05	0.00226	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—HCAR2—psoriasis	5.89e-05	0.00226	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—TAGAP—psoriasis	5.82e-05	0.00223	CbGpPWpGaD
Dextropropoxyphene—OPRK1—GPCR downstream signaling—CCL20—psoriasis	5.7e-05	0.00218	CbGpPWpGaD
Dextropropoxyphene—CYP3A7—Metabolism—NDUFA5—psoriasis	5.45e-05	0.00209	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Peptide ligand-binding receptors—CXCL8—psoriasis	5.34e-05	0.00204	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling by GPCR—CCL20—psoriasis	5.18e-05	0.00198	CbGpPWpGaD
Dextropropoxyphene—OPRD1—G alpha (i) signalling events—CXCL8—psoriasis	5.13e-05	0.00197	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—TAGAP—psoriasis	5.11e-05	0.00196	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—HCAR2—psoriasis	4.98e-05	0.00191	CbGpPWpGaD
Dextropropoxyphene—OPRM1—GPCR downstream signaling—CCL20—psoriasis	4.82e-05	0.00185	CbGpPWpGaD
Dextropropoxyphene—CYP3A7—Metabolism—CYP2S1—psoriasis	4.63e-05	0.00177	CbGpPWpGaD
Dextropropoxyphene—OPRM1—TCR Signaling Pathway—IL6—psoriasis	4.61e-05	0.00176	CbGpPWpGaD
Dextropropoxyphene—Quinapril—ACE—psoriasis	4.59e-05	1	CrCbGaD
Dextropropoxyphene—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	4.51e-05	0.00173	CbGpPWpGaD
Dextropropoxyphene—OPRK1—G alpha (i) signalling events—CXCL8—psoriasis	4.5e-05	0.00172	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling by GPCR—CCL20—psoriasis	4.38e-05	0.00168	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—TAGAP—psoriasis	4.32e-05	0.00165	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.08e-05	0.00156	CbGpPWpGaD
Dextropropoxyphene—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	3.8e-05	0.00146	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.58e-05	0.00137	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—CCL20—psoriasis	3.49e-05	0.00134	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Metabolism—NDUFA5—psoriasis	3.41e-05	0.00131	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.18e-05	0.00122	CbGpPWpGaD
Dextropropoxyphene—OPRD1—GPCR ligand binding—CXCL8—psoriasis	3.11e-05	0.00119	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—CCL20—psoriasis	3.06e-05	0.00117	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.02e-05	0.00116	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Metabolism—CYP2S1—psoriasis	2.9e-05	0.00111	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Metabolism—NDUFA5—psoriasis	2.8e-05	0.00107	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Metabolism—NDUFA5—psoriasis	2.78e-05	0.00106	CbGpPWpGaD
Dextropropoxyphene—OPRK1—GPCR ligand binding—CXCL8—psoriasis	2.73e-05	0.00104	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.59e-05	0.000991	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—CCL20—psoriasis	2.59e-05	0.00099	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Metabolism—CYP2S1—psoriasis	2.38e-05	0.000912	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Metabolism—CYP2S1—psoriasis	2.36e-05	0.000904	CbGpPWpGaD
Dextropropoxyphene—OPRM1—GPCR ligand binding—CXCL8—psoriasis	2.3e-05	0.000882	CbGpPWpGaD
Dextropropoxyphene—CYP3A7—Metabolism—CARM1—psoriasis	2.26e-05	0.000866	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—SOCS1—psoriasis	1.92e-05	0.000736	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling by GPCR—TYK2—psoriasis	1.83e-05	0.000702	CbGpPWpGaD
Dextropropoxyphene—CYP3A4—Metabolism—NDUFA5—psoriasis	1.83e-05	0.000701	CbGpPWpGaD
Dextropropoxyphene—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	1.76e-05	0.000673	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—SOCS1—psoriasis	1.68e-05	0.000645	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling by GPCR—TYK2—psoriasis	1.61e-05	0.000615	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling by GPCR—CXCL8—psoriasis	1.6e-05	0.000611	CbGpPWpGaD
Dextropropoxyphene—CYP3A4—Metabolism—CYP2S1—psoriasis	1.56e-05	0.000596	CbGpPWpGaD
Dextropropoxyphene—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	1.54e-05	0.00059	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.52e-05	0.000582	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—SOCS1—psoriasis	1.42e-05	0.000545	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—APOE—psoriasis	1.42e-05	0.000543	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—LEP—psoriasis	1.42e-05	0.000543	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Metabolism—CARM1—psoriasis	1.42e-05	0.000542	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling by GPCR—CXCL8—psoriasis	1.4e-05	0.000536	CbGpPWpGaD
Dextropropoxyphene—CYP3A7—Metabolism—CAT—psoriasis	1.39e-05	0.000533	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling by GPCR—TYK2—psoriasis	1.36e-05	0.00052	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.32e-05	0.000507	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—NFKBIA—psoriasis	1.32e-05	0.000506	CbGpPWpGaD
Dextropropoxyphene—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	1.3e-05	0.000499	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—LEP—psoriasis	1.24e-05	0.000476	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—APOE—psoriasis	1.24e-05	0.000476	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.24e-05	0.000474	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling by GPCR—CXCL8—psoriasis	1.18e-05	0.000453	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Metabolism—CARM1—psoriasis	1.16e-05	0.000445	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—NFKBIA—psoriasis	1.16e-05	0.000444	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Metabolism—CARM1—psoriasis	1.15e-05	0.000441	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—TYK2—psoriasis	1.08e-05	0.000414	CbGpPWpGaD
Dextropropoxyphene—CYP3A7—Metabolism—APOE—psoriasis	1.08e-05	0.000414	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.08e-05	0.000413	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—APOE—psoriasis	1.05e-05	0.000402	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—LEP—psoriasis	1.05e-05	0.000402	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—NFKBIA—psoriasis	9.79e-06	0.000375	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—TYK2—psoriasis	9.49e-06	0.000363	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—CXCL8—psoriasis	9.42e-06	0.000361	CbGpPWpGaD
Dextropropoxyphene—CYP3A7—Metabolism—PPARG—psoriasis	9.41e-06	0.000361	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling by GPCR—IL6—psoriasis	8.96e-06	0.000343	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—JUN—psoriasis	8.76e-06	0.000336	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Metabolism—CAT—psoriasis	8.71e-06	0.000334	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—NFKB1—psoriasis	8.43e-06	0.000323	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—CXCL8—psoriasis	8.26e-06	0.000316	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—TYK2—psoriasis	8.02e-06	0.000307	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling by GPCR—IL6—psoriasis	7.86e-06	0.000301	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—JUN—psoriasis	7.68e-06	0.000294	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—VEGFA—psoriasis	7.65e-06	0.000293	CbGpPWpGaD
Dextropropoxyphene—CYP3A4—Metabolism—CARM1—psoriasis	7.6e-06	0.000291	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—STAT3—psoriasis	7.58e-06	0.00029	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—NFKB1—psoriasis	7.39e-06	0.000283	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Metabolism—CAT—psoriasis	7.15e-06	0.000274	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Metabolism—CAT—psoriasis	7.09e-06	0.000271	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—CXCL8—psoriasis	6.98e-06	0.000267	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Metabolism—APOE—psoriasis	6.77e-06	0.000259	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—VEGFA—psoriasis	6.71e-06	0.000257	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—STAT3—psoriasis	6.64e-06	0.000254	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling by GPCR—IL6—psoriasis	6.64e-06	0.000254	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—JUN—psoriasis	6.49e-06	0.000249	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—NFKB1—psoriasis	6.25e-06	0.000239	CbGpPWpGaD
Dextropropoxyphene—CYP2C8—Metabolism—PPARG—psoriasis	5.89e-06	0.000226	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—TP53—psoriasis	5.78e-06	0.000221	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—VEGFA—psoriasis	5.67e-06	0.000217	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—STAT3—psoriasis	5.62e-06	0.000215	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Metabolism—APOE—psoriasis	5.56e-06	0.000213	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Metabolism—APOE—psoriasis	5.51e-06	0.000211	CbGpPWpGaD
Dextropropoxyphene—OPRD1—Signaling Pathways—IL6—psoriasis	5.29e-06	0.000203	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—TP53—psoriasis	5.07e-06	0.000194	CbGpPWpGaD
Dextropropoxyphene—CYP2D6—Metabolism—PPARG—psoriasis	4.84e-06	0.000185	CbGpPWpGaD
Dextropropoxyphene—CYP2C9—Metabolism—PPARG—psoriasis	4.8e-06	0.000184	CbGpPWpGaD
Dextropropoxyphene—CYP3A4—Metabolism—CAT—psoriasis	4.67e-06	0.000179	CbGpPWpGaD
Dextropropoxyphene—OPRK1—Signaling Pathways—IL6—psoriasis	4.64e-06	0.000178	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—TP53—psoriasis	4.29e-06	0.000164	CbGpPWpGaD
Dextropropoxyphene—OPRM1—Signaling Pathways—IL6—psoriasis	3.92e-06	0.00015	CbGpPWpGaD
Dextropropoxyphene—CYP3A4—Metabolism—APOE—psoriasis	3.63e-06	0.000139	CbGpPWpGaD
Dextropropoxyphene—CYP3A4—Metabolism—PPARG—psoriasis	3.16e-06	0.000121	CbGpPWpGaD
